TUCSON, Ariz. – October 14, 2026 – Siensmetrica, Inc., developer of the AI-powered Tessa research evaluation platform, today announced that it has changed its corporate name to Tessa AI, Inc. The change, effective October 7, 2026, brings the company’s name in line with the platform that its customers, partners, and the broader research community already know it by.

Tessa takes its name from T.E.S. (Transparency, Explainability, and Significance), the framework at the core of the company’s technology. Since its public launch in May 2026, Tessa has helped researchers, clinicians, reviewers, and biopharma professionals evaluate the trustworthiness of biomedical research, analyzing more than 200 data points per paper and showing the evidence behind every score.

From measuring research to supporting its entire life

The original name, Siensmetrica, was a coined word meaning roughly “knowledge measurement.” It described where the company began: a system for scoring the quality of published research. Scoring remains central to what the company does, but it is now one part of a much larger mission.

Tessa AI is building a suite of research analysis, discovery, and data science tools on the Tessa platform and the research data that powers it. Together, they are designed to support a study across its entire life: helping authors strengthen a manuscript before it is submitted, helping research teams survey an entire field of literature in a fraction of the time it takes today, helping the public tell whether a news story or podcast accurately reflects the research behind it, and evaluating work published years or even decades earlier. Company Chief Science Officer Marvin J. Slepian, MD, JD, describes this arc as the “natural history of scientific research.” All of the new tools will carry the Tessa name.

“For a while now, our customers, partners, and even our own team have simply called us Tessa,” said Marc Toth, CEO of Tessa AI. “Siensmetrica described where we started. Tessa describes where we’re going. We’re building tools that will be part of research from the moment a question is first asked to long after the answer is published, and it made sense for the company to carry the name people already associate with that work.”

A system ready for change

The way science is produced, reviewed, and judged has struggled to keep pace with the volume of research now being published. Peer review is stretched thin and, in some cases, gamed. Citation counts can be padded. Prestige metrics such as journal rank and author reputation often stand in for an actual evaluation of the work, and retractions and reproducibility failures continue to erode public trust in science.

Tessa AI’s leadership team, made up of serial technology innovators who have built and disrupted businesses before, believes the research enterprise is overdue for the same kind of change. The company’s recent decision to remove author reputation from the TScore, so that papers are judged on their methods and evidence rather than the names on the title page, offers an early look at that approach.

“Every study has a natural history: an idea, a design, an experiment, a publication, and a long afterlife of citation, replication, and sometimes correction,” said Dr. Slepian. “Today, most of the tools that touch that history were built for a slower world. Our goal is to bring transparency and rigor to every stage of it, so that good science can be recognized for what it is, wherever it comes from.”

The first of the new Tessa products is expected to launch in the coming weeks, with more to follow.

Visitors to siensmetrica.com will be redirected to the new site, and company email addresses are moving to the @tessaai.co domain.

About Tessa AI, Inc.

Tessa AI, Inc. (formerly Siensmetrica, Inc.) develops Tessa, an AI-powered platform that evaluates the trustworthiness of biomedical and healthcare research. Built on the T.E.S. (Transparency, Explainability, and Significance) framework, Tessa uses coordinated, specialized AI agents to assess a paper’s methodology, citations, reporting completeness, and risk of bias, and shows the evidence behind every score. The company is building a family of Tessa tools to support scientific research across its full lifecycle. Learn more at www.tessaai.co.

###

FOR IMMEDIATE RELEASE

TUCSON, Ariz. – May 19, 2026 — Siensmetrica today announced the public release of Tessa, an AI-powered platform designed to help researchers, clinicians, reviewers, and healthcare professionals evaluate the integrity and reliability of biomedical and healthcare research more efficiently.

Available immediately at no cost to users with a Google or Google Workspace account, Tessa applies Siensmetrica’s proprietary T.E.S. (Transparency, Explainability, and Significance) framework to analyze scientific literature in minutes, helping reduce the time traditionally required for detailed research review and validation.

The platform is intended to support a broad range of users across the scientific and medical community, including academic medical centers, biopharma organizations, peer reviewers, policy analysts, clinicians, and independent researchers seeking clearer insight into study quality and methodological rigor.

Rather than functioning solely as a summarization tool, Tessa uses a coordinated system of specialized AI agents trained in biomedical research methodologies, evaluation frameworks, and scientific review practices. These agents independently assess findings and cross-validate conclusions before generating a final analysis.

Tessa is organized into three analytical modules designed to address different levels of research evaluation needs:

Analytical Modules

Search, Score & Save

Designed for clinicians, researchers, and general readers seeking a fast assessment of a paper’s credibility and relevance.

• T-Score: Evaluates more than 200 indicators across five categories — methodology, author metrics, journal impact, media coverage, and authenticity signals — to generate an overall trustworthiness score from 0 to 100.
• Visual Quality Indicators: Uses color-coded tagging to provide quick reference indicators for paper quality and reliability.
• Research Summaries: Summarizes a study’s objectives, findings, conclusions, and field-specific contributions.
• Ecosystem Mapping: Generates interactive relationship maps connecting authors, institutions, collaborators, and funding organizations.
• Integrity Review Tools: Links to Google Scholar author profiles and extracts study figures for reverse-image lookup to help identify duplicate image usage online.
• Personal Research Library: Allows users to save and organize evaluated papers for future reference.

Citation Analysis

Designed for academic institutions, peer reviewers, publishers, and organizations producing or evaluating scientific literature.

• Reference Verification: Cross-checks citations against major biomedical databases including PubMed, Embase, Scopus, and MEDLINE to identify unverified or potentially problematic references.
• Contextual Citation Review: Evaluates whether cited sources appropriately support the claims made within a paper.
• Anomaly Detection: Flags potential concerns such as excessive self-citation, citation padding, retracted references, or post-publication citation inconsistencies.
• Citation Relevance Scoring: Assigns relevance scores to individual citations and provides an aggregate citation assessment for the publication.

Deep Dive Analysis

Developed for biopharma organizations, policymakers, funding groups, and other stakeholders conducting high-level scientific due diligence.

• Methodology Classification: Identifies study type, model systems, and supporting textual evidence used in the analysis.
• Scientific Rigor Assessment: Evaluates study completeness and methodological rigor across 11 domains, including hypothesis clarity, control adequacy, statistical analysis, dose-response validation, and replication quality.
• Protocol Evaluation: Provides structured assessments of protocol design, assessability, supporting evidence, and methodological adequacy.
• Strategic Research Insights: Highlights strengths, limitations, and areas where additional validation or methodological refinement may be warranted.

Integration with Zotero

To support existing scientific research workflows, Tessa integrates with Zotero, the widely used open-source research management platform. The integration enables users to import, score, and organize large collections of scientific papers in bulk, helping researchers identify higher-quality studies more efficiently. Additional third-party integrations are currently in development.

Availability

Tessa is now publicly available with no subscription fees, contracts, or credit card requirements.

• Access Tessa: www.tessapp.ai
• Learn more about Siensmetrica: siensmetrica.com

###

Siensmetrica is pleased to announce that we have officially joined the NVIDIA Inception program.

This milestone marks an exciting step forward as we continue building tools that bring greater trust, transparency, and rigor to scientific research.

The NVIDIA Inception program is designed to help startups accelerate innovation and growth. As a member, Siensmetrica gains access to important developer resources and technical training that will support the continued evolution of Tessa, our research analysis platform. These resources will help us strengthen Tessa’s capabilities and ensure it remains robust, reliable, and ready to meet the growing need for trustworthy scientific evaluation.

At Siensmetrica, our mission has always been to raise the standard of integrity in research. Partnering with NVIDIA through the Inception program helps us move faster toward that goal. We’re excited for what this collaboration will unlock and look forward to applying these new tools to advance our platform—and, ultimately, scientific progress itself.

Stay tuned for more updates as we continue innovating with the support of NVIDIA Inception.

Dr. Eva Redei and Dr. Jeremy Worley join advisory board to deepen company’s expertise in evaluating biomedical research

October 1, 2025 — Siensmetrica today announced the appointment of two distinguished scientists, Dr. Eva E. Redei and Dr. Jeremy Worley, to the company’s advisory board.

Siensmetrica’s mission is to enable medical professionals to quickly identify and utilize high-quality research. While the advisory board has deep expertise from the clinical perspective, the additions of Dr. Redei and Dr. Worley bring an invaluable researcher’s viewpoint, strengthening the orgainzation’s ability to evaluate the quality, clarity, and scientific soundness of bio-medical research.

About the Board Members

Eva E. Redei, MS, PhD
Dr. Redei is a Professor Emeritus in Psychiatry and Behavioral Sciences at Northwestern University’s Feinberg School of Medicine. With over 150 publications and 15 patents, her extensive career has focused on identifying biomarkers for depressive disorders. Her experience serving on NIH review panels and the editorial boards of prestigious journals like Molecular Psychiatry gives her an unparalleled understanding of what constitutes rigorous, impactful research.

Dr. Jeremy Worley, PhD
Dr. Worley is an Assistant Professor in Systems Biology at Columbia University Irving Medical Center and a Chan Zuckerberg Biohub New York investigator. His work at the forefront of computational biology and CRISPR-based genome engineering provides critical insight into the modern tools and methodologies driving today’s most advanced research. Dr. Worley’s experience in both academic and private sector settings is directly relevant to our work at the intersection of science and technology.

“The addition of these two accomplished researchers ensures that our Tessa software platform is built on a comprehensive understanding of the entire research ecosystem from lab to clinic,” Siensmetrica CEO, Marc Toth said. “Their guidance will be instrumental as we continue to refine our methodologies for scoring and surfacing the most credible and significant biomedical studies.”

About Siensmetrica

Siensmetrica’s mission is to help medical professionals deliver better care and improve outcomes by quickly and easily identifying high quality, trustworthy scientific information. The company’s Tessa platform uses a framework—Transparency, Explainability, and Significance or “T.E.S.”— that taps same sort of reasoning heuristics humans do to analyze and assess the quality of bio-medical research. Tessa evaluates nearly 200 variables within research to derive a clear overall score, five sub-scores, and detailed explanations that make it simple to quickly differentiate high quality, trustworthy material from inferior product. For more information, visit the Siensmetrica website at www.siensmetrica.com or via email at info@siensmetrica.com.

###

Media contact:
A. Sage Osterfeld
press@siensmetrica.com

Exciting News! We’re thrilled to announce the formation of our Advisory Board, a diverse team of experts who will guide us in revolutionizing the way medical professionals and researchers assess the trustworthiness of scientific literature.

Our mission is to leverage cutting-edge data analysis and AI to empower healthcare professionals with the tools to identify the most reliable and impactful research quickly. With the expertise of our Advisory Board, we’re one step closer to achieving this vision.

The board brings together a wealth of expertise across critical fields. It includes a renowned PhD in computer science specializing in AI innovation; three accomplished physicians with backgrounds in cardiology, rheumatology, and anesthesiology, who offer diverse clinical insights; a noted medical researcher and assistant professor of microbiology and immunology with a deep understanding of scientific rigor; and a former biopharma executive with decades of leadership experience in advancing medical innovation. This unique blend of expertise ensures that our platform is grounded in both cutting-edge technology and practical, real-world applicability.

This incredible team will help us develop a solution that transforms how healthcare decisions are informed—saving time, improving outcomes, and advancing trust in science.